The regional specificity between tau and cognitive impairment has been demonstrated in the context of early-onset, non-amnestic forms of AD, where clinical variants exhibit different topographies of tau that are consistent with the clinical phenotype [24, 25]. The gene discussed is MAPT; the disease is Cognitive impairment.